IntrinsicIntrinsic
← All summaries

4D Molecular Therapeutics, Inc.

FDMT
Financials & Chart →

Business Summary

The company, 4D Molecular Therapeutics, Inc. (FDMT), is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics using its proprietary Therapeutic Vector Evolution (TVE) platform . This platform applies directed evolution principles in non-human primate (NHP) models to select adeno-associated virus (AAV) vectors that target specific tissues for diseases with high unmet medical needs, using routine and local routes of administration . The core business model revolves around generating revenue through collaboration and license agreements, primarily from upfront and milestone payments, and expense reimbursements, as the company has not yet generated any revenue from product sales . Primary customer segments for its collaboration agreements appear to be large pharmaceutical companies and foundations, such as Otsuka Pharmaceutical Co., Ltd. and the Cystic Fibrosis Foundation .

FDMT's product pipeline is concentrated in two therapeutic areas: retina and pulmonology . In the retina therapeutic area, the lead product candidate is 4D-150, which utilizes the proprietary R100 vector and a dual transgene payload expressing aflibercept and VEGF-C RNAi . 4D-150 is designed as a backbone therapy for chronic retinal vascular diseases, initially targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) . Wet AMD affects an estimated 5 million patients, and DME affects an estimated 4 million patients in the United States, major European markets, and Japan . The global branded therapeutic markets for bolus anti-VEGF treatment of retinal vascular diseases exceed $16 billion, with wet AMD and DME comprising approximately $14 billion . The second retina product candidate is 4D-175 for geographic atrophy, which has an open Investigational New Drug (IND) application, with further development pending financing .

In the pulmonology therapeutic area, the company is developing product candidates using its customized and evolved A101 vector, designed for aerosol delivery and resistance to pre-existing antibodies in humans . The first pulmonology product candidate is 4D-710 for cystic fibrosis (CF) lung disease, which is currently in Phase 2 development . CF is considered a rare disease, affecting nearly 40,000 people in the United States and an estimated 105,000 people worldwide . The second pulmonology product candidate is 4D-725 for alpha-1 antitrypsin deficiency lung disease, which is in preclinical development and fully funded by the California Institute for Regenerative Medicine through IND filing .

For the fiscal year ended December 31, 2025, the company reported collaboration and license revenue of $85.209 million , a significant increase from $37 thousand in 2024 . Total operating expenses were $244.756 million , leading to a loss from operations of $159.547 million . Other income, net, was $19.438 million , resulting in a net loss of $140.109 million . As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $514.0 million and an accumulated deficit of $716.3 million .

Comparing the years ended December 31, 2025, and 2024, revenue increased by $85.172 million , primarily due to upfront fees from the Otsuka Collaboration and License Agreement in October 2025 . Research and development expenses increased by $54.397 million, or 38% , driven by a $35.5 million increase in trials and consumables for product candidates, primarily 4D-150 , a $10.0 million increase in payroll and personnel expenses due to increased headcount and severance costs , and an $8.9 million increase in facilities and other R&D expenses . General and administrative expenses increased by $2.5 million, or 5% , mainly due to higher legal and consulting services . Other income, net, decreased by $7.5 million, or 28% , due to reduced invested balances and lower market yields .

Significant operational developments during the period include the initiation of the 4FRONT-1 Phase 3 trial for 4D-150 in wet AMD in March 2025, with enrollment completion announced in February 2026, ahead of projections . The 4FRONT-2 Phase 3 trial for 4D-150 in wet AMD was initiated in June 2025 . Positive long-term interim results from the PRISM Phase 1/2 clinical trial for 4D-150 in wet AMD were reported in November 2025, showing consistent and durable benefit with up to 2 years of follow-up and a 79-94% reduction in treatment burden across cohorts . Positive 60-week topline interim data from Part 1 of the SPECTRA Phase 1/2 clinical trial for 4D-150 in DME were announced in July 2025, with the 3E10 vg/eye dose selected for Phase 3, demonstrating a 78% reduction in supplemental injections versus projected on-label aflibercept 2mg Q8W . In October 2025, the company entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. for 4D-150 in Japan, China, Australia, and other APAC markets, including an $85.0 million upfront cash payment and potential milestones up to $335.5 million . In December 2025, positive interim clinical data from the AEROW Phase 1 stage for 4D-710 in cystic fibrosis were announced, showing consistent and dose-dependent CFTR transgene RNA levels and clinically meaningful activity . The 2.5E14 vg dose was selected as the Phase 2 dose . In July 2025, a workforce reduction of approximately 25% of current and planned roles was announced, resulting in a $3.2 million expense .

Business Outlook

The company anticipates topline data for the 4FRONT-1 Phase 3 trial of 4D-150 in wet AMD in the first half of 2027 , and for the 4FRONT-2 Phase 3 trial in the second half of 2027 . For 4D-150 in DME, a single global Phase 3 clinical trial is expected to initiate in the third quarter of 2026, with approximately 300-400 patients . The company believes its existing cash, cash equivalents, and marketable securities of $514.0 million as of December 31, 2025, will fund planned operations for at least one year from the issuance date of the financial statements .

A major growth area is the continued advancement of 4D-150 for wet AMD and DME. The company's strategy focuses on advancing 4D-150 through Phase 3 trials and, if successful, commercialization . The goal for 4D-150 is to transform the standard of care for large market retinal vascular diseases with a safe, in-office, and durable lifelong backbone therapy, substantially reducing treatment burden and improving long-term vision outcomes . The global branded therapeutic markets for bolus anti-VEGF treatment of retinal vascular diseases, including wet AMD and DME, exceed $16 billion . The company has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for 4D-150 for both wet AMD and DME, and PRIority MEdicine (PRIME) designation from the EMA for wet AMD, highlighting regulatory recognition of its potential . The recent collaboration with Otsuka Pharmaceutical Co., Ltd. grants exclusive development and commercialization rights for 4D-150 in Japan, China, Australia, and other Asia-Pacific markets, with potential regulatory and commercial milestone payments up to $335.5 million and tiered double-digit royalties on net sales .

Another significant growth area is the development of 4D-710 for cystic fibrosis lung disease. The company is currently enrolling the Phase 2 portion of the AEROW Phase 1/2 clinical trial for 4D-710 . 4D-710 is designed as a durable, redosable, variant-agnostic disease-modifying therapy for CF lung disease, intended for efficient aerosol delivery and resistance to pre-existing antibodies . The company initially plans to focus on the approximately 15% of people with CF who are not amenable to CFTR modulators, representing a high unmet need . The Cystic Fibrosis Foundation has committed up to $11 million in additional funding, including an initial $7.5 million tranche received in October 2025, to support the Phase 2 stage of the AEROW clinical trial, redosing, and Phase 3 readiness activities .

The company expects its overall research and development expenses to increase in the near term, primarily due to the 4D-150 Phase 3 trials in wet AMD and DME . In July 2025, the company announced a workforce reduction of approximately 25% of current and planned roles, primarily in early-stage research and development and support functions, resulting in a $3.2 million expense in 2025 . This restructuring reflects a strategic pipeline prioritization to focus on 4D-150 and 4D-710 . The company's manufacturing strategy involves continually developing and scaling its in-house manufacturing platform for GMP and non-GMP manufacturing, and it also collaborates with contract development and manufacturing organizations (CDMOs) to supplement internal capacity, expecting to rely on CDMOs for potential commercial supply . The company has completed the tech transfer of produced and released Phase 3 batches using its intended commercial processes at a leading global commercial CDMO for 4D-150 .

The company will require substantial additional funding to support its continuing operations and further development of its product candidates . It intends to obtain this funding through equity offerings, debt financings, or other third-party funding, including additional potential strategic alliances and licensing or collaboration arrangements . The company's patent strategy includes filing patent applications covering unique gene sequences selected through its TVE process, and it also relies on trade secrets, know-how, and in-licensing opportunities . As of February 14, 2026, its solely owned patent portfolio includes eighteen granted U.S. patents and one hundred and thirty-five granted foreign patents, expected to expire between May 2037 and April 2042 .

Risk Factors

The company faces significant risks due to its limited operating history and lack of approved products, with recurring net losses of $140.1 million and $160.9 million for 2025 and 2024, respectively, and an accumulated deficit of $716.3 million as of December 31, 2025 . Substantial additional capital will be required to finance operations, and inability to raise such capital could force delays or elimination of research and development programs or commercialization efforts . All product candidates are based on novel AAV genetic medicine technology with limited regulatory and clinical experience, making development time and cost difficult to predict and potentially longer and more expensive than for other therapeutic modalities . Adverse public perception or regulatory scrutiny of genetic medicine technology could negatively impact development or commercial success . Clinical trials may fail to demonstrate substantial evidence of safety and efficacy, leading to delays or denial of regulatory approval . Gene therapies are complex to manufacture, and production problems could cause delays, limit supply, or harm the business . The regulatory approval processes are lengthy, expensive, and unpredictable, and failure to obtain approval would prevent product revenue generation . The company's success depends on protecting its intellectual property, and its rights to develop and commercialize product candidates are subject to licenses from others, with patent protection, prosecution, and enforcement potentially dependent on licensors . Employees, contractors, and partners may engage in misconduct, including noncompliance with regulatory standards . Unfavorable global economic conditions, including increased inflation and interest rates, could adversely affect the business and ability to raise capital . The company's reliance on Chinese biotechnology companies, CROs, and CDMOs may subject it to additional risks from trade restrictions, sanctions, or proposed legislation like the U.S. BIOSECURE Act, which could increase costs or reduce supply . Cybersecurity risks, including attacks and breaches, could disrupt operations, lead to data loss, regulatory delays, or loss of competitive advantages . The evolving regulatory framework for AI Technologies, including potential for deficient AI-generated content or increased regulatory scrutiny, could negatively impact the business .

Management Priorities

Management emphasizes the company's position as a leading late-stage biotechnology company focused on advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms. A key strategic priority is the advancement of 4D-150 for wet AMD and DME through late-stage studies and potential commercialization, as evidenced by the initiation of the 4FRONT-1 and 4FRONT-2 Phase 3 trials in March 2025 and June 2025, respectively . Management anticipates topline data for 4FRONT-1 in the first half of 2027 and for 4FRONT-2 in the second half of 2027 . Another strategic priority is advancing other pipeline programs, specifically 4D-710 for CF lung disease and 4D-725 for A1AT lung disease, primarily through external funding and strategic partnerships . The company has secured a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for 4D-150 in APAC markets, including an $85.0 million upfront cash payment and potential milestone payments up to $335.5 million . Additionally, a funding agreement with the Cystic Fibrosis Foundation provides up to $11 million in additional funding for 4D-710, with $7.5 million received in October 2025, enabling the start of the Phase 2 stage of the AEROW clinical trial . Management believes that existing cash, cash equivalents, and marketable securities of $514.0 million as of December 31, 2025, will fund planned operations for at least one year from the date of the financial statements .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Components of Results of Operations — Revenue
  3. [3] Item 1, Business — Strategic Collaborations
  4. [4] Item 1, Business — Our Product Candidate Pipeline & Strategy
  5. [5] Item 1, Business — 4D-150 for Wet AMD and DME — Our Solution
  6. [6] Item 1, Business — 4D-150 for Wet AMD and DME — Disease Background, Unmet Medical Need, and Target Patient Population
  7. [7] Item 1, Business — 4D-150 for Wet AMD and DME — Disease Background, Unmet Medical Need, and Target Patient Population
  8. [8] Item 1, Business — Pulmonology Therapeutic Area Introduction
  9. [9] Item 1, Business — 4D-710 for Cystic Fibrosis Lung Disease — Disease Background, Unmet Medical Need, and Target Patient Population
  10. [10] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  11. [11] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  12. [12] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  13. [13] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  14. [14] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  15. [15] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  16. [16] Item 7, MD&A — Liquidity and Capital Resources — Sources of Liquidity
  17. [17] Item 7, MD&A — Overview
  18. [18] Item 7, MD&A — Results of Operations — Revenue
  19. [19] Item 7, MD&A — Results of Operations — Revenue
  20. [20] Item 7, MD&A — Results of Operations — Research and Development Expenses
  21. [21] Item 7, MD&A — Results of Operations — Research and Development Expenses
  22. [22] Item 7, MD&A — Results of Operations — Research and Development Expenses
  23. [23] Item 7, MD&A — Results of Operations — Research and Development Expenses
  24. [24] Item 7, MD&A — Results of Operations — General and Administrative Expenses
  25. [25] Item 7, MD&A — Results of Operations — General and Administrative Expenses
  26. [26] Item 7, MD&A — Results of Operations — Other Income, Net
  27. [27] Item 7, MD&A — Results of Operations — Other Income, Net
  28. [28] Item 7, MD&A — Overview
  29. [29] Item 7, MD&A — Overview
  30. [30] Item 7, MD&A — Overview
  31. [31] Item 7, MD&A — Overview
  32. [32] Item 7, MD&A — Overview
  33. [33] Item 7, MD&A — Overview
  34. [34] Item 1, Business — Clinical Development: AEROW Phase 1/2 Clinical Trial
  35. [35] Item 7, MD&A — Restructuring and Other Charges
  36. [36] Item 7, MD&A — Overview
  37. [37] Item 7, MD&A — Overview
  38. [38] Item 1, Business — Clinical Development of 4D-150 in DME: SPECTRA Phase 1/2 Clinical Trial
  39. [39] Item 7, MD&A — Future Funding Requirements
  40. [40] Item 1, Business — Our Product Candidate Pipeline & Strategy
  41. [41] Item 1, Business — Overview
  42. [42] Item 1, Business — 4D-150 for Wet AMD and DME — Disease Background, Unmet Medical Need, and Target Patient Population
  43. [43] Item 1, Business — Differentiation of 4D-150
  44. [44] Item 1, Business — Strategic Collaborations — Otsuka Pharmaceutical Co., Ltd.
  45. [45] Item 1, Business — Pulmonology Therapeutic Area Introduction
  46. [46] Item 1, Business — 4D-710 for Cystic Fibrosis Lung Disease — Our Solution
  47. [47] Item 1, Business — 4D-710 for Cystic Fibrosis Lung Disease — Our Solution
  48. [48] Item 7, MD&A — Overview
  49. [49] Item 7, MD&A — Future Funding Requirements
  50. [50] Item 7, MD&A — Restructuring and Other Charges
  51. [51] Item 7, MD&A — Restructuring and Other Charges
  52. [52] Item 1, Business — Manufacturing CMC Strategy
  53. [53] Item 1, Business — External Manufacturing
  54. [54] Item 7, MD&A — Future Funding Requirements
  55. [55] Item 7, MD&A — Future Funding Requirements
  56. [56] Item 1, Business — Intellectual Property
  57. [57] Item 1, Business — Intellectual Property
  58. [58] Item 1A, Risk Factors — Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements
  59. [59] Item 1A, Risk Factors — Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements
  60. [60] Item 1A, Risk Factors — Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates
  61. [61] Item 1A, Risk Factors — Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates
  62. [62] Item 1A, Risk Factors — Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates
  63. [63] Item 1A, Risk Factors — Risks Related to Manufacturing
  64. [64] Item 1A, Risk Factors — Risks Related to Regulatory Approval and Other Legal Compliance Matters
  65. [65] Item 1A, Risk Factors — Risks Related to Our Intellectual Property
  66. [66] Item 1A, Risk Factors — General Risk Factors
  67. [67] Item 1A, Risk Factors — Risks Related to Our Operations
  68. [68] Item 1A, Risk Factors — Risks Related to Our Reliance on Third Parties
  69. [69] Item 1A, Risk Factors — Risks Related to Our Operations
  70. [70] Item 1A, Risk Factors — Risks Related to Our Operations
  71. [71] Item 7, MD&A — Overview
  72. [72] Item 7, MD&A — Overview
  73. [73] Item 7, MD&A — Overview
  74. [74] Item 7, MD&A — Overview
  75. [75] Item 7, MD&A — Overview
  76. [76] Item 7, MD&A — Future Funding Requirements

Analysis on 5/21/2026